During Tuesday’s Afternoon trade, Shares of Alamos Gold Inc. Class A (NYSE:AGI), lost -3.12% to $3.72.
Alamos Gold Inc. (AGI) stated financial results for the quarter ended June 30, 2015 and reviewed its operating, exploration and development activities.
Merger with AuRico Gold Inc.
On April 13, 2015, Former Alamos declared a definitive agreement with AuRico to combine the respective companies by way of a Plan of Arrangement (the “Arrangement”), creating a new, leading intermediate gold producer. The Merger combined two top-quality, highly-complementary asset portfolios, counting two long-life, cash flow generating gold mines: AuRico’s Young-Davidson mine in Ontario, Canada and Former Alamos’ Mulatos mine in Sonora, Mexico.
The Arrangement was accomplished on July 2, 2015 and AuRico and Former Alamos amalgamated to form Alamos. As part of the Arrangement, certain assets of AuRico, counting the Kemess project, a 1.5% net smelter return royalty on the Young-Davidson mine, AuRico’s Fosterville and Stawell royalties, and $20 million of cash, were transferred to a new company, AuRico Metals Inc. (“AuRico Metals”). About 95.1% of the common shares of AuRico Metals were distributed to Former Alamos and AuRico shareholders. Following completion of the Arrangement, the Company held an equity interest of about 4.9% in AuRico Metals.
Alamos Gold, Inc. operates as an intermediate gold producer primarily in North America. The company primarily holds a 100% interest in the Young-Davidson gold mine, which comprises mineral leases and claims totaling 11,000 acres in Northern Ontario, Canada.
Shares of GLOBAL BLOOD THERAPEUTICS INC COM USD0.001 (NASDAQ:GBT), declined -10.37% to $47.94, during its Afternoon trading session.
Global Blood Therapeutics, Inc. (GBT) is a clinical stage biopharmaceutical company dedicated to discovering, developing and commercializing novel, small molecule therapeutics to treat grievous blood-based disorders with noteworthyunmet need. GBT is developing its initial product candidate, GBT440, as an oral, once-daily prophylactic therapy for sickle cell disease (SCD) and is presently evaluating GBT440 in both healthy subjects and SCD patients in a randomized, placebo-controlled, double-blind Phase 1/2 clinical trial. In addition to GBT440 for the treatment of SCD, GBT is engaged in research and development activities targeted toward hypoxemic pulmonary disorders, counting idiopathic pulmonary fibrosis, and hereditary angioedema.
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in double-blind Phase I/II clinical trial indicated for the treatment of sickle cell disease. The company also focuses on developing an oral prophylactic therapy for hypoxemic pulmonary disorders and hereditary angioedema. The company was founded in 2011 and is based in South San Francisco, California.
Applied Micro Circuits Corporation (NASDAQ:AMCC), during its Tuesday’s Afternoon trading session decreased -3.60% to $5.63.
Applied Micro Circuits Corporation (AMCC) stated its financial results for the fiscal 2016 first quarter ended June 30, 2015.
Fiscal Q1 2016 Financial Information
- Merged net revenue of $37.8 million
- GAAP net loss of $7.4 million or $0.09 per share
- Non-GAAP net loss of $3.3 million or $0.04 per share
- Total cash, cash equivalents and short-term investments of about $76.6 million as of June 30, 2015
AppliedMicro provides non-GAAP results as additional information regardingits financial condition and business trends. This information should be considered in conjunction with corresponding GAAP measures. A reconciliation between GAAP and non-GAAP financial results is offered in the financial tables section of this press release.
Applied Micro Circuits Corporation provides silicon solutions for next-generation cloud infrastructure and data centers; and connectivity products for edge, metro, and long haul communications equipment in the United States and internationally. The company offers X-Gene, a server on a chip product for use in cloud data center, computing, and enterprise applications; and embedded computing products that are applied in control- and data-plane administration, wireless access points, residential gateways, wireless base stations, storage controllers, network attached storage, network switches and routing products, and multi-function printers.
Finally, INC Research Holdings Inc (NASDAQ:INCR), gained 0.01%, to $44.45.
INC Research Holdings, Inc. (INCR), a leading global Phase I to Phase IV contract research organization, declared the pricing of its secondary offering of 8,000,000 shares of its Class A common stock by certain of its existing stockholders, counting associates of Avista Capital Partners, L.P.; associates of Teachers’ Private Capital, the private investment arm of Ontario Teachers’ Pension Plan Board; and current and former employees of INC Research. INC Research will not receive any proceeds from the sale of the shares by the selling stockholders in this offering. The closing of the offering is predictable to occur on August 17, 2015, subject to customary closing conditions.
Credit Suisse Securities (USA) LLC and J.P. Morgan Securities LLC are the joint book-running managers for the offering.
INC Research Holdings, Inc., a contract research organization, provides various clinical development services for the biopharmaceutical and medical device industries. The company offers a range of services focusing on Phase I to Phase IV clinical trials in the areas of central nervous system, oncology, and other complex diseases, such as genetic disorders and infectious diseases. Its services comprise clinical trial administration services comprising patient recruitment and retention, project administration, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services comprising of clinical data administration, electronic data capture, and biostatistics.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
